静脉血管紧张素Ⅱ治疗血管扩张性休克并接受肾脏替代治疗患者的结局
该研究为Angiotensin II for the Treatment of High-Output Shock 3试验的事后分析,纳入在启动研究药物时因急性肾损伤接受肾脏替代治疗的ICU患者,血管紧张素Ⅱ组45例、安慰剂组60例,均为静脉给药。主要终点28天生存率血管紧张素Ⅱ组53%(95%CI 38%-67%)vs安慰剂组30%(95%CI 19%-41%),P=0.012。第7天脱离肾脏替代治疗比例血管紧张素Ⅱ组38%(95%CI 25%-54%)vs安慰剂组15%(95%CI 8%-27%),P=0.007。平均动脉压反应率(较基线升高≥10 mmHg或第3小时升至≥75 mmHg)血管紧张素Ⅱ组53%(95%CI 38%-68%)vs安慰剂组22%(95%CI 12%-34%),P=0.001。作者认为此类患者可能优先从血管紧张素Ⅱ获益。
要点
- 血管扩张性休克合并需肾脏替代治疗的急性肾损伤患者中,血管紧张素Ⅱ组28天生存率53% vs 安慰剂组30%(P=0.012)。
- 第7天脱离肾脏替代治疗比例血管紧张素Ⅱ组38% vs 安慰剂组15%(P=0.007),血管紧张素Ⅱ组更高。
- 平均动脉压反应率血管紧张素Ⅱ组53% vs 安慰剂组22%(P=0.001),反应定义为较基线升高≥10 mmHg或第3小时升至≥75 mmHg。
- 该分析为Angiotensin II for the Treatment of High-Output Shock 3试验的事后分析,血管紧张素Ⅱ组45例、安慰剂组60例。
- 作者认为需肾脏替代治疗的血管扩张性休克合并急性肾损伤患者可能优先从血管紧张素Ⅱ获益。
适用人群与场景
- ICU中血管扩张性休克且因急性肾损伤在启动研究药物时接受肾脏替代治疗的患者,血管紧张素Ⅱ组45例、安慰剂组60例。
诊断标准与关键阈值
- 平均动脉压反应标准:较基线升高≥10 mmHg或第3小时升至≥75 mmHg。
处置流程与药物剂量
- 静脉给予血管紧张素Ⅱ或安慰剂,具体剂量原文未给出。
研究设计与关键结果
- 研究类型为Angiotensin II for the Treatment of High-Output Shock 3试验的事后分析,纳入ICU中因急性肾损伤接受肾脏替代治疗并启动研究药物的患者,血管紧张素Ⅱ组45例、安慰剂组60例,干预为静脉血管紧张素Ⅱ或安慰剂。
- 主要终点28天生存率:血管紧张素Ⅱ组53%(95%CI 38%-67%)vs 安慰剂组30%(95%CI 19%-41%),P=0.012。
- 第7天脱离肾脏替代治疗比例:血管紧张素Ⅱ组38%(95%CI 25%-54%)vs 安慰剂组15%(95%CI 8%-27%),P=0.007。
- 平均动脉压反应率:血管紧张素Ⅱ组53%(95%CI 38%-68%)vs 安慰剂组22%(95%CI 12%-34%),P=0.001;反应定义为较基线升高≥10 mmHg或第3小时升至≥75 mmHg。
- 作者结论:需肾脏替代治疗的血管扩张性休克合并急性肾损伤患者,血管紧张素Ⅱ组28天生存率和平均动脉压反应率更高、脱离肾脏替代治疗比例更大,此类患者可能优先从血管紧张素Ⅱ获益。
证据类型、等级与局限
- 证据类型:Angiotensin II for the Treatment of High-Output Shock 3试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,血管扩张性休克合并急性肾损伤且需肾脏替代治疗的患者可能优先从血管紧张素Ⅱ获益;该结论来自事后分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy.
DESIGN: Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial.
PATIENTS: Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo (n = 45 and n = 60, respectively).
INTERVENTIONS: IV angiotensin II or placebo.
MEASUREMENTS AND MAIN RESULTS: Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of ≥ 10 mm Hg or increase to ≥ 75 mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%-67%) and 30% (95% CI, 19%-41%) in patients treated with angiotensin II and placebo (p = 0.012), respectively. By day 7, 38% (95% CI, 25%-54%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%-27%) placebo (p = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%-68%) and 22% (95% CI, 12%-34%) of patients treated with angiotensin II and placebo (p = 0.001), respectively.
CONCLUSIONS: In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II.
参考来源
- Tumlin JA, Murugan R, Deane AM, et al. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med. 2018. PMID: 29509568. doi:10.1097/CCM.0000000000003092
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。